IGEA announces launch of Alz1

Hoofddorp, the Netherlands, 14 July 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced the launch of Alz1, the first solution designed to detect and reduce high free copper levels in the bloodstream – a risk factor associated with Alzheimer’s disease – through a first-of-its-kind in-home blood test and a dietary supplement for those with elevated free copper levels.

Read More

IGEA announces annual general meeting resolutions

Hoofddorp, The Netherlands, 6 June 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced that the annual general meeting followed all recommendations of the Company.

Read More

IGEA discloses its Q1 2019 financials

Hoofddorp, The Netherlands, 27 May 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced the disclosure of its Q1 2019 financials.

Read More

IGEA discloses its Annual Report 2018

Hoofddorp, The Netherlands, 30 April 2019. IGEA Pharma N.V. (the “Company” and together with its subsidiaries “IGEA” or the “Group”) today announced the disclosure of its Annual Report 2018.
Highlights

Read More

Update of the corporate calendar

Hoofddorp, the Netherlands, 28 March 2019. IGEA Pharma N.V. (SIX: IGPH) today announced an update of its corporate calendar. The annual general meeting is newly set-up for 27 May 2019. The presentation of the 2018 financials and the Q1 2019 financials is newly set-up for 26 April 2019 and 27 May 2019 respectively. The update is due to some additional work necessary to harmonize with SIX and Dutch disclosure requirements. The updated corporate calendar is available under igeapharma.nl/investors-relations/

Read More

Listing of IGEA Pharma N.V.

Amsterdam, December 17, 2018. IGEA Pharma N.V. announced today that it will list all of its ordinary shares on SIX Swiss Exchange as of December 20, 2018 under the ticker symbol ‘IGPH’.

Read More